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Neurotrophic factor‑based strategies 
to enhance survival and differentiation 
of neural progenitor cells toward the 
dopaminergic phenotype
Stefano Di Santo, Hans R. Widmer
Abstract:
Parkinson’s disease (PD) is a neurodegenerative disorder that presents with hallmark clinical 
symptoms of tremor at rest, bradykinesia, and muscle rigidity. Stem cell therapy has emerged 
as an experimental treatment for PD. However, optimizing the cell culture condition that allows 
enhanced survival and differentiation of cells toward the dopaminergic phenotype remains a logistical 
challenge. Here, we discuss the utility of a combination of neurotrophin‑4/5 (NT‑4/5) and glial cell 
line‑derived neurotrophic factor (GDNF) in increasing the dopaminergic phenotypic expression of 
rat ventral mesencephalic (VM) tissue. Using organotypic explant cultures of fetal human ventral 
mesencephalon, we observed that NT‑4/5 and GDNF as single factors, or in combination on DAergic 
neurons, increased survival and number of tyrosine hydroxylase immunoreactive neurons as well as 
the dopamine content in the culture medium. The application of specific neurotrophic factors, such as 
NT-4/5 and GDNF, as cell culture supplements or as adjunctive therapy to cell transplantation may 
achieve improved functional outcomes when contemplating cell-based regenerative medicine for PD.
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Introduction
Parkinson’s disease (PD) is characterized by loss of dopaminergic (DAergic) 
neurons in the substantia nigra pars 
compacta. Drugs therapies are currently 
available for the treatment of PD, however 
long-term pharmacological treatment is often 
accompanied by serious side effects. Stem 
cell therapy has been suggested as potent 
treatment for PD because they may represent 
as robust biological source of dopamine.
Stem Cell Therapy for Parkinson’s 
Disease
I t  h a s  b e e n  d e m o n s t r a t e d  t h a t 
transplantation of human fetal nigral 
tissue is safe and may reinnervate the 
dopamine-depleted striatum in PD patients.
[1-4] However, the survival of DAergic 
neurons limits the efficacy of this transplant 
strategy.[1] In this regard, nonfetal tissue 
sources of dopamine have been examined 
in an attempt to increase DAergic survival; 
along this line of investigation, induced 
pluripotent stem cells and embryonic 
stem cells have been evaluated as rich 
sources of DAergic neurons, but their 
potential to restore the striatum function 
is still under investigation.[5] Another 
interesting approach to increase the 
survival of DAergic neurons either in 
culture or following transplantation could 
be the use of neurotrophic factors. In this 
context, glial cell line-derived neurotrophic 
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factor (GDNF) and neurotrophin-4/5 (NT-4/5) support 
the improved growth and survival of DAergic neurons.[6] 
Neurotrophic signaling pathways may be involved in 
these observed cell-surviving effects. In particular, GDNF 
is a member of the transforming growth factor-beta 
superfamily and promotes DAergic survival and 
differentiation by activating a multicomponent receptor 
complex called RET and the GDNF family receptor. 
Interestingly, GDNF increased high‑affinity dopamine 
uptake in cultures of the fetal midbrain, improving 
DAergic viability and stimulating differentiation.[7,8] 
On the other hand, NT-4/5 belongs to the NT family 
and triggers a signaling pathway that involves the rat 
sarcoma-phosphatidylinositol 3-kinase-Protein Kinase 
B (Ras-PI3K-Akt) and the phospholipase C-gamma 1.[9,10] 
NT-4/5 can regulate the morphology and improve the 
survival of DAergic neurons in mesencephalic primary 
cultures.[11,12] The administration of GDNF and NT-4/5 
increased the survival of rat ventral mesencephalic (VM) 
tyrosine hydroxylase immunoreactive (TH-ir) neurons 
along with stimulation of dopamine (DA) release in 
free‑floating roller‑tube (FFRT) cultures.[6] In addition, 
the ability of donor tissue storage in FFRT cultures 
supports the strategy to pretreat the cells with growth 
factors. Of note, in this respect, DAergic viability and 
functions have been restored in a rat model of PD by 
using fibroblast growth factor 2‑mediated pregrafting 
expansion of primary VM precursor cells.[13,14] To 
date, most studies have only explored the effects of 
monotherapy of neurotrophic factors on DAergic cell 
survival. Here, we discuss our experiments evaluating 
the therapeutic potential of combined GDNF and 
NT-4/5 administration on VM tissue of human origin 
in an attempt to reveal the application of neurotrophic 
factors as cell culture supplement or as an adjunct 
therapy for cell transplantation in PD.
Neurotrophic Factor Treatment of Neural 
Progenitor Cells
We assessed the survival and differentiation potential 
of organotypic explants of the fetal human VM when 
cultured with or without GDNF and NT-4/5 singly or 
combined pretreatment. The combined pretreatment 
increased both cell number and DA content of TH-ir 
neurons better than using singular treatments of 
either neurotrophic factors alone. In addition, no 
difference is observed in culture volumes, while the 
level of lactate dehydrogenase in culture medium was 
decreased in all the treatment conditions. These findings 
advance our current knowledge on the contribution of 
neurotrophic factors for DAergic neurons in animal 
models.[6] Indeed, it has been demonstrated that the 
GDNF reduces apoptosis and stimulates DAergic fiber 
growth in DAergic neurons and fetal nigral grafts, 
respectively.[15,16] Moreover, GDNF and NT-4/5 reduce 
oxidative stress-induced cell death, which is implicated 
in PD and other neurodegenerative diseases, through 
an anti-apoptotic mechanism.[17,18] The reduction of 
apoptosis might be one of the events underlying the 
observed NT-4/5 and GDNF protective action in 
TH-ir neurons. In addition, the decrease of lactic acid 
dehydrogenase (LDH) levels after GDNF and NT-4/5 
treatment offer an alternative mechanism. That LDH 
levels are not lower in the GDNF and NT-4/5 combined 
treatment than the single neurotrophic factor treatment 
suggests that the synergistic action of GDNF and 
NT-4/5 is not a direct action on cell death reduction, but 
rather an increase of maturation and/or differentiation 
of the TH-ir cells. Indeed, no significant variation 
in culture volume is observed between the different 
experimental conditions. In addition, the treatment 
with neurotrophic factors has no influence on the 
protein GFAP expression levels, as shown previously.[6] 
In contrast, this neurotrophic factor treatment could 
promote the survival and the growth of other neuronal 
cells including striatal and cortical GABAergic 
neurons,[9,19-21] suggesting the preferential effects of 
GDNF and NT-4/5 on the neuronal phenotype.
Several lines of investigation suggest that the pretreatment 
of DAergic neurons with neurotrophic factors may be a 
potential strategy for the PD treatment. In this context, we 
showed that both number of cultured DAergic neurons 
and DA levels increased after BDNF treatment.[22] In 
addition, the combined action of GDNF and BDNF 
promoted the survival of rat fetal nigral tissue.[16] 
There remain some discrepant reports on the effects of 
neurotrophic factors on cell survival and differentiation. 
For example, dopamine levels may correlate with 
the TH-ir cell number even though no growth factor 
treatment was applied; in contrast, a prominent increase 
in dopamine levels is achieved with the combined 
GDNF and BDNF treatment compared to the use of 
these neurotrophic factors individually.[16,23] Notably, a 
clinical study reported increased uptake of fluorodopa 
in 2 PD patients when graft is exposed to GDNF.[24] 
Further investigations are needed to better understand 
the benefit of GDNF and NT4/5 pretreatment in cultured 
cells of potential DAergic graft donors, as well as the 
effects of these neurotrophic factors as adjunct treatments 
in clinically relevant animal models of PD.
Conclusion
In conclusion, these findings on combined pretreatment 
with neurotrophic factors of DAergic neurons support 
the potential of this strategy for enhancing the survival 
and differentiation of neural progenitor cells as graft 
source for transplantation therapy in PD. Adjunctive 
use of neurotrophic factors with cell therapy may also 
reveal improved functional outcomes.
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